Olema Pharmaceuticals (OLMA) Research & Development (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Research & Development data on file, last reported at $49.2 million in Q1 2026.

• On a quarterly basis, Research & Development rose 60.76% year-over-year to $49.2 million in Q1 2026; TTM through Mar 2026 was $176.3 million, a 40.75% increase from a year earlier, with the FY2025 full-year figure at $157.7 million, up 26.65% from the prior year.
• Research & Development for Q1 2026 stood at $49.2 million, up from $43.2 million in the prior quarter.
• Over the last five years, Research & Development for OLMA reached as high as $49.2 million in Q1 2026 and fell as low as $16.0 million in Q1 2022.
• Historically, Research & Development has averaged $29.4 million across 5 years, with a median of $29.1 million in 2024.
• Across the five-year window, Research & Development jumped 127.15% in 2022 and slumped 33.51% in 2023, its largest moves.
• Year by year, Research & Development stood at $21.6 million in 2022, then increased by 19.87% to $25.9 million in 2023, then climbed by 24.84% to $32.3 million in 2024, then jumped by 33.81% to $43.2 million in 2025, then gained by 13.91% to $49.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $49.2 million in Q1 2026, $43.2 million in Q4 2025, and $40.0 million in Q3 2025.